期刊
TUMOR BIOLOGY
卷 35, 期 10, 页码 9823-9830出版社
SAGE PUBLICATIONS LTD
DOI: 10.1007/s13277-014-2282-5
关键词
Breast cancer; Neoadjuvant chemotherapy; Estrogen receptor; Progesterone receptor; HER2 receptor; Neutrophil/lymphocyte ratio
类别
The aim of this study was to determine the predictive or prognostic impact of absolute neutrophil count/absolute lymphocyte count ratio (NLR) in breast cancer patients with estrogen receptor/progesterone receptor (ER/PR)-positive and human epidermal growth factor receptor 2 (HER2)-negative subtype who have received neoadjuvant chemotherapy (NAC). We performed retrospective analysis of 157 patients with primary breast cancer with ER/PR-positive and HER2-negative subtype who were treated with NAC, followed by definitive surgical resection. The median follow-up after surgery was 21 months (range, 1-108 months). On univariate analysis, high NLR (>2.25) correlated with poorer recurrence-free survival (RFS) and overall survival (OS) (P=0.001 and P<0.001). Subgroup analysis of non-pathologic complete response (pCR) subgroup showed that high NLR was significant for RFS and OS (P=0.001 and P<0.001). Particularly, high NLR patients had inferior clinical outcomes in the high clinical stage. Uni- and multivariate Cox analysis showed NLR to be an only predictor of RFS and OS. The NLR is an independent prognostic factor for RFS and OS in breast cancer patients with ER/PR-positive and HER2-negative subtype receiving NAC. The NLR provides additional prognostic information to choose suitable patients who might profit from further therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据